Occudo Quantitative Strategies LP Relmada Therapeutics, Inc. Transaction History

Occudo Quantitative Strategies LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.22 - $3.54 $36,006 - $57,415	-16,219 Reduced 41.42%	22,941 $56,000
Q1 2023 May 15, 2023	SELL	$2.24 - $4.76 $205,074 - $435,782	-91,551 Reduced 70.04%	39,160 $88,000
Q4 2022 Feb 14, 2023	BUY	$2.17 - $35.84 $283,642 - $4.68 Million	130,711 New	130,711 $456,000
Q2 2021 Aug 16, 2021	SELL	$29.55 - $39.15 $168,671 - $223,468	-5,708 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$31.52 - $39.28 $31,740 - $39,554	-1,007 Reduced 15.0%	5,708 $201,000
Q4 2020 Feb 16, 2021	BUY	$29.88 - $39.8 $200,644 - $267,257	6,715 New	6,715 $215,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Occudo Quantitative Strategies LP, based on Form 13F filings with the SEC.

Stay updated on Occudo Quantitative Strategies LP with notifications on news.